tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

CTMX Stock Latest News

CytomX Therapeutics Reports Q3 2025 Financial Results
Company AnnouncementsCytomX Therapeutics Reports Q3 2025 Financial Results
1d ago
CTMX
CytomX Therapeutics reports Q3 EPS (9c), consensus (4c)
PremiumThe Fly
CytomX Therapeutics reports Q3 EPS (9c), consensus (4c)
2d ago
CTMX
CytomX Therapeutics Advances CX-2051 Study in Solid Tumors
PremiumCompany Announcements
CytomX Therapeutics Advances CX-2051 Study in Solid Tumors
12d ago
CTMX
Cautious Hold Rating on CytomX Therapeutics Amid Safety Concerns and Awaited Phase 1 Data for CX-2051
PremiumRatings
Cautious Hold Rating on CytomX Therapeutics Amid Safety Concerns and Awaited Phase 1 Data for CX-2051
12d ago
CTMX
CytomX Therapeutics management to meet with Oppenheimer
PremiumThe Fly
CytomX Therapeutics management to meet with Oppenheimer
18d ago
CTMX
CytomX Therapeutics price target raised to $6 from $3.50 at Barclays
PremiumThe FlyCytomX Therapeutics price target raised to $6 from $3.50 at Barclays
18d ago
CTMX
CytomX Therapeutics appoints Rachael Lester as chief business officer
Premium
The Fly
CytomX Therapeutics appoints Rachael Lester as chief business officer
19d ago
CTMX
Oppenheimer positive on CytomX after Merus colon cancer data
Premium
The Fly
Oppenheimer positive on CytomX after Merus colon cancer data
25d ago
CTMX
MRUS
CytomX Therapeutics: Hold Rating Amid Awaited CX-801 Data and Market Potential
PremiumRatings
CytomX Therapeutics: Hold Rating Amid Awaited CX-801 Data and Market Potential
1M ago
CTMX
CytomX Therapeutics initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
CytomX Therapeutics initiated with an Overweight at Cantor Fitzgerald
2M ago
CTMX
CytomX Therapeutics initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
CytomX Therapeutics initiated with an Overweight at Cantor Fitzgerald
2M ago
CTMX
CytomX Therapeutics assumed with an Overweight at Barclays
PremiumThe Fly
CytomX Therapeutics assumed with an Overweight at Barclays
2M ago
CTMX
CytomX Therapeutics initiated with an Overweight at Barclays
PremiumThe FlyCytomX Therapeutics initiated with an Overweight at Barclays
2M ago
CTMX
Barclays sees ‘significant potential’ in CytomX’s CX-2051 despite safety event
Premium
The Fly
Barclays sees ‘significant potential’ in CytomX’s CX-2051 despite safety event
3M ago
CTMX
CytomX trial ongoing despite grade five event, says Oppenheimer
Premium
The Fly
CytomX trial ongoing despite grade five event, says Oppenheimer
3M ago
CTMX
CytomX Therapeutics Updates on CX-2051 Phase 1 Study
PremiumCompany Announcements
CytomX Therapeutics Updates on CX-2051 Phase 1 Study
3M ago
8K
CTMX
CytomX Therapeutics provides update on CX-2051 Phase 1 study
PremiumThe Fly
CytomX Therapeutics provides update on CX-2051 Phase 1 study
3M ago
CTMX
CytomX Therapeutics Earnings Call: Clinical Progress and Financial Strength
PremiumCompany Announcements
CytomX Therapeutics Earnings Call: Clinical Progress and Financial Strength
3M ago
CTMX
Promising Clinical Progress and Efficacy of CytomX Therapeutics’ CX-2051 Justifies Buy Rating
PremiumRatings
Promising Clinical Progress and Efficacy of CytomX Therapeutics’ CX-2051 Justifies Buy Rating
3M ago
CTMX
CytomX Therapeutics Reports Strong Financial Turnaround
PremiumCompany AnnouncementsCytomX Therapeutics Reports Strong Financial Turnaround
3M ago
CTMX
CytomX Therapeutics reports Q2 EPS 0c, consensus (6c)
Premium
The Fly
CytomX Therapeutics reports Q2 EPS 0c, consensus (6c)
3M ago
CTMX
CytomX Therapeutics files $250M mixed securities shelf
Premium
The Fly
CytomX Therapeutics files $250M mixed securities shelf
3M ago
CTMX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >